AstraZeneca Bets $1.2 Billion on CSPC's Weight-Loss Drug Pipeline in Major China Deal
British pharmaceutical giant AstraZeneca has entered a strategic partnership with China's CSPC Pharmaceutical, committing over $1 billion upfront to co-develop next-generation obesity therapies, signaling intensified competition in the lucrative global weight-loss drug market.